[Effect of intra-thoracic administration of an immune modulator (OK-432) with anti-cancer drugs (ADR and MMC)].
Fourty-three patients with pleuritis carcinomatosa have been treated with an intra-thoracic administration in four distinct ways: Adriamycin alone, OK-432 alone, the combination of Adriamycin with OK-432, or the combination of Mitomycin C with OK-432. Judging from an evaluation of the subsequent chest X-rays, the prognosis of the cases which received the combination therapy of the two drugs was significantly better to that of the others. There were no significant differences between cases with primary lung cancer and those with other cancers. As for the side effects after the administration, there were no side effects, such as the trouble the renal function or liver function, other than fever and a decrease in the W.B.C.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000627:therapeutic use; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007267:Injections / Q000379:methods; D007970:Leukopenia / Q000139:chemically induced; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications*; D010844:Picibanil / Q000008:administration & dosage* / Q000627:therapeutic use; D010998:Pleurisy / Q000188:drug therapy* / Q000209:etiology; D011379:Prognosis; D013909:Thorax
D000276:Adjuvants, Immunologic; D001688:Biological Products; D008937:Mitomycins; D010844:Picibanil; D016685:Mitomycin; D004317:Doxorubicin